We are live on ! Find out more
WHWK

Whitehawk Therapeutics

68 hedge funds and large institutions have $159M invested in Whitehawk Therapeutics in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

24% more funds holding

Funds holding: 5568 (+13)

2.36% more ownership

Funds ownership: 60.85%63.21% (+2.4%)

21% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 19

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

27% less capital invested

Capital invested by funds: $219M → $159M (-$59.9M)

Holders
68
Holders Change
+13
Holders Change %
+23.64%
% of All Funds
1.15%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
23
Increased
15
Reduced
19
Closed
10
Calls
$2.79M
Puts
Net Calls
+$2.79M
Net Calls Change
+$940K
Name Holding Trade Value Shares
Change
Change in
Stake
Manulife (Manufacturers Life Insurance)
26
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$499K +$177K +11,945 +45%
Charles Schwab
27
Charles Schwab
California
$491K +$592K +39,850 New
Bank of America
28
Bank of America
North Carolina
$416K -$391K -26,350 -44%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$373K -$983K -66,175 -69%
Millennium Management
30
Millennium Management
New York
$369K -$2.54M -170,936 -85%
AICPI
31
ABG Innovation Capital Partners III
Hong Kong
$329K
TD Asset Management
32
TD Asset Management
Ontario, Canada
$297K -$159K -10,700 -31%
Morgan Stanley
33
Morgan Stanley
New York
$286K -$187K -12,593 -35%
N
34
Nuveen
North Carolina
$258K +$311K +20,913 New
Marshall Wace
35
Marshall Wace
United Kingdom
$242K -$1.06M -71,521 -79%
Rafferty Asset Management
36
Rafferty Asset Management
New York
$220K -$340K -22,918 -56%
Citigroup
37
Citigroup
New York
$218K -$123K -8,300 -32%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$209K +$252K +16,996 New
UBS Group
39
UBS Group
Switzerland
$202K -$598K -40,250 -71%
CSS
40
Cubist Systematic Strategies
Connecticut
$191K +$40.3K +2,712 +21%
DMKJ
41
David M. Knott Jr
$173K +$209K +14,039 New
NRS
42
Neville Rodie & Shaw
New York
$164K +$198K +13,333 New
BFM
43
Boothbay Fund Management
New York
$157K -$643K -43,319 -77%
AA
44
ALPS Advisors
Colorado
$153K -$134K -9,046 -42%
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$140K +$169K +11,395 New
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$123K +$149K +10,000 New
MIM
47
MetLife Investment Management
New Jersey
$96.1K +$116K +7,802 New
JP Morgan Chase
48
JP Morgan Chase
New York
$95K +$115K +7,742 New
Deutsche Bank
49
Deutsche Bank
Germany
$89K +$108K +7,283 New
AIG
50
American International Group
New York
$83K +$101K +6,777 New

WHWK Hedge Fund Activity: Q2 2022 in Review

68 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2022, worth a combined $159M — down 27% from $219M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new WHWK positions and 10 closed out — a net gain of 13 holders — while 15 added to existing stakes and 19 trimmed.

The largest buyer was BlackRock, adding an estimated $8.8M. The largest seller was RK Capital Management (Colorado), exiting entirely with an estimated $5.36M sold.

  • 68 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2022, up from 55 in Q1 2022.
  • Funds reported $159M of Whitehawk Therapeutics stock for Q2 2022, down 27% quarter-over-quarter.
  • 23 funds opened new Whitehawk Therapeutics positions in Q2 2022 and 10 closed out, a net change of +13 holders.
  • The largest Whitehawk Therapeutics buyer in Q2 2022 was BlackRock, an estimated $8.8M added.
  • The largest Whitehawk Therapeutics seller in Q2 2022 was RK Capital Management (Colorado), an estimated $5.36M sold.

Based on aggregated 13F filings for Q2 2022.